236 related articles for article (PubMed ID: 16482569)
1. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
[TBL] [Abstract][Full Text] [Related]
2. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
7. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Chudley L; McCann K; Mander A; Tjelle T; Campos-Perez J; Godeseth R; Creak A; Dobbyn J; Johnson B; Bass P; Heath C; Kerr P; Mathiesen I; Dearnaley D; Stevenson F; Ottensmeier C
Cancer Immunol Immunother; 2012 Nov; 61(11):2161-70. PubMed ID: 22729556
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
9. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP
Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355
[TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
11. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
12. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
13. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.
Cunha AC; Weigle B; Kiessling A; Bachmann M; Rieber EP
Cancer Lett; 2006 May; 236(2):229-38. PubMed ID: 16046056
[TBL] [Abstract][Full Text] [Related]
15. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
16. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
[TBL] [Abstract][Full Text] [Related]
17. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
Wieckowski E; Chatta GS; Mailliard RM; Gooding W; Palucka K; Banchereau J; Kalinski P
Prostate; 2011 Feb; 71(2):125-33. PubMed ID: 20717900
[TBL] [Abstract][Full Text] [Related]
18. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M
Br J Cancer; 2004 Mar; 90(5):1034-40. PubMed ID: 14997204
[TBL] [Abstract][Full Text] [Related]
19. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
Knight D; Peterson AC; Rini BI; Harlin H; Gajewski TF; Stadler WM
Prostate; 2009 Feb; 69(2):142-8. PubMed ID: 18942640
[TBL] [Abstract][Full Text] [Related]
20. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Murphy GP; Tjoa BA; Simmons SJ; Jarisch J; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL
Prostate; 1999 Jan; 38(1):73-8. PubMed ID: 9973112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
